Although pharmacologic VEGF inhibition appears to be effective across a spectrum of neovascular retinal diseases, genome editing produces a cellular mosaic of homozygous null mutants which could be impacted by compensatory paracrine effects from neighboring cells or upregulation of other proangiogenic pathways. The gene discussed is VEGFA; the disease is Abnormal retinal morphology.